LAUSR

ARAF Mutations Limit Response to RAF Dimer Inhibition.

Sign Up to like & get
recommendations!
1 Published in 2021 at "Cancer discovery"

DOI: 10.1158/2159-8290.cd-rw2021-069

Abstract: Belvarafenib is active in BRAF- and NRAS-mutant tumors, but acquired ARAF mutations drive resistance. read more here.

Keywords: mutations limit; limit response; raf dimer; araf mutations ... See more keywords